Refractive evaluation in thalidomide embryopathy.
To evaluate the ocular findings associated with thalidomide embryopathy, we examined 86 of 100 Swedes who had a proven correlation between birth defects and the mother's intake of thalidomide during pregnancy. Cycloplegic refraction, keratometry, and axial length measurements were performed. The subjects were divided into four groups according to their physical malformations, giving a time frame for when in gestation the insult occurred (the sensitive phase for thalidomide is 20-36 days after conception). The results indicate a trend toward shorter and longer axial lengths, high refractive errors, and corneal astigmatism in thalidomide embryopathy compared to controls, and in addition there was a tendency for those anomalies to occur in the group with the earliest thalidomide-induced defects. It is suggested that thalidomide disturbs the growth and shape of the eye and that this effect is exerted early in its teratogenic period.
Strömland
K
K
Department of Pediatric Ophthalmology, University of Göteborg, East Hospital, Sweden.
Miller
M T
MT
D000014:Abnormalities, Drug-Induced / Q000473:pathology / Q000503:physiopathology; D000015:Abnormalities, Multiple / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D000328:Adult; D003315:Cornea / Q000002:abnormalities / Q000473:pathology / Q000503:physiopathology; D005124:Eye Abnormalities / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008850:Microphthalmos / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D012030:Refractive Errors / Q000503:physiopathology*; D013792:Thalidomide / Q000009:adverse effects*; D014792:Visual Acuity
D013792:Thalidomide